Find policies, billing codes, payers, states, and providers

HCPCS Level II M0233: Tocilizumab Intravenous Infusion, First Dose for Hospitalized Adults

HCPCS Level II code M0233 identifies the first-dose intravenous infusion of tocilizumab-aazg for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. This code captures the infusion procedure and immediate post-administration monitoring for the initial dose. Nationally, the code matters because it standardizes reporting and billing for a targeted biologic therapy used in severe COVID-19 cases, affecting hospital billing workflows and payer coverage decisions.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find information on service definitions, typical sites of service, and the clinical context for use. The publication provides benchmarks and comparative guidance on how payers recognize and reimburse this hospital-based infusion service, highlights relevant policy updates impacting coverage and documentation, and outlines operational considerations for hospitals and billing teams. This summary is written for a national audience seeking clarity on coding, billing, and payer handling of first-dose tocilizumab infusions for severe COVID-19 in hospitalized adults.

Customize your policy alerts

Sign up for hcpcs M0233 policy alerts

Get alerted when payer policies referencing M0233 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

HCPCS Level II code M0233 represents an intravenous infusion of tocilizumab-aazg, first dose, for hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The description includes the infusion procedure and post-administration monitoring for the first dose.

Service type: Intravenous monoclonal antibody infusion, first dose
Typical site of service: Hospital inpatient settings, including intensive care units and other inpatient wards providing supplemental oxygen, non-invasive or invasive ventilation, or ECMO

Find policies, billing codes, payers, states, and providers

HCPCS Level II M0233: Tocilizumab Intravenous Infusion, First Dose for Hospitalized Adults

Customize your policy alerts

Sign up for hcpcs M0233 policy alerts

Get alerted when payer policies referencing M0233 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Service type: Intravenous monoclonal antibody infusion, first dose
Typical site of service: Hospital inpatient settings, including intensive care units and other inpatient wards providing supplemental oxygen, non-invasive or invasive ventilation, or ECMO

Clinical & Coding Specifications

Clinical Context

A 67-year-old hospitalized patient with severe COVID-19 presents with progressive hypoxemic respiratory failure. The patient is receiving systemic corticosteroids and requires supplemental oxygen via high-flow nasal cannula. The treating team determines the patient meets criteria for immunomodulatory therapy with tocilizumab. After informed consent, the pharmacy verifies weight-based dosing for M0233 (first dose), the nursing team places a peripheral or central IV line, and the infusion is prepared under aseptic technique. The infusion is administered with continuous monitoring of vital signs during the infusion and for a period afterward to observe for infusion reactions and clinical response. Laboratory monitoring (including CBC, liver enzymes, and inflammatory markers) is obtained before and after administration per institutional protocol. If the patient progresses to non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), documentation reflects ongoing need for supplemental oxygen and systemic corticosteroid therapy to support billing under M0233.

Coding Specifications

Modifier	Description	When to Use
`25`	Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure	When an E/M visit meets criteria in addition to the infusion service on the same date
`59`	Distinct procedural service	When another non-overlapping procedure is performed the same day and documentation supports distinct service
`76`	Repeat procedure or service by same physician	When the first-dose infusion is repeated by the same provider on the same day for clinical reasons
`77`	Repeat procedure by another physician	When a different physician repeats the infusion procedure on the same day
`90`	Reference (Outside) Laboratory	When laboratory testing associated with the infusion is performed by an outside reference lab
`91`	Repeat clinical diagnostic laboratory test	When an identical lab test is repeated within the same encounter for clinical reasons
`Q0`	Investigational clinical service provided in a clinical research study, not otherwise specified	If the infusion is provided under a clinical trial protocol that uses this modifier per payer rules
`Q5`	Service furnished under a clinic consortium agreement	When applicable per contractual arrangements with participating entities
`GA`	Waiver of liability statement on file (patient refuses payment)	When a signed Advance Beneficiary Notice or similar is on file for payors that require it
`G0`	Emergency use of a non‑approved device or service	If applicable for payors recognizing emergency use authorization circumstances

Taxonomy Code	Specialty	Notes
`207RC0000X`	Infectious Disease	Consultants who recommend and manage immunomodulatory therapy
`2084P0800X`	Critical Care Medicine	Intensivists managing mechanically ventilated or ECMO patients
`207K00000X`	Allergy & Immunology	Specialists involved in cytokine-modulating therapy decisions
`207L00000X`	Pulmonary Disease	Pulmonologists managing severe COVID-19 respiratory failure
`163W00000X`	Hospitalist	Hospital-based physicians who coordinate inpatient ordering and administration

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J12.82`	Pneumonia due to coronavirus disease 2019 (COVID-19)	Primary diagnosis indicating viral pneumonia requiring supplemental oxygen and qualifying for tocilizumab
`J96.01`	Acute respiratory failure with hypoxia	Indicates respiratory compromise often present in patients receiving `M0233`
`J80`	Acute respiratory distress syndrome	Severe pulmonary inflammation that may prompt use of immunomodulatory therapy
`R09.02`	Hypoxemia	Describes the need for supplemental oxygen documented for `M0233` eligibility
`B97.29`	Other coronavirus as the cause of diseases classified elsewhere	Alternate coding for COVID-19-related conditions when applicable

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	May be used for other IV infusions given before or after the tocilizumab infusion when billed separately
`96366`	Each additional hour (list separately in addition to code for primary infusion)	When the infusion duration extends beyond the initial hour and payer allows separate reporting
`36415`	Collection of venous blood by venipuncture	Performed before infusion for baseline labs (CBC, CMP, liver enzymes)
`99223`	Initial hospital care, typically 70 minutes or more	Hospitalist or intensivist initial admission evaluation for a critically ill patient who will receive `M0233`
`93000`	Electrocardiogram, routine ECG with at least 12 leads; tracing and interpretation	Performed when cardiac monitoring or baseline ECG is clinically indicated prior to immunomodulatory therapy

HCPCS M0075: Cellular Therapy Processing and Provision

HCPCS-M0076-PROLOTHERAPY-INJECTION-THERAPY

HCPCS M0076: Prolotherapy Injection Therapy

HCPCS-M0100-INTRAGASTRIC-HYPOTHERMIA-GASTRIC-FREEZING

HCPCS M0100: Intragastric Hypothermia Using Gastric Freezing

HCPCS-M0201-IN-HOME-VACCINE-ADMINISTRATION

HCPCS M0201: In-Home Administration of Pneumococcal/Influenza/Hep B/COVID-19 Vaccine

HCPCS-M0220-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS

HCPCS M0220: Tixagevimab and Cilgavimab Injection for Pre-Exposure Prophylaxis

HCPCS-M0221-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS-HOME-ADMINISTRATION

HCPCS M0221: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

HCPCS-M0222-BEBTELOVIMAB-INTRAVENOUS-INJECTION-MONITORING

HCPCS M0222: Intravenous Injection of Bebtelovimab, Includes Monitoring

HCPCS-M0223-BEBTELOVIMAB-INTRAVENOUS-INJECTION-HOME-MONITORING

HCPCS M0223: Bebtelovimab IV Injection with Home Monitoring

HCPCS-M0224-PEMIVIBART-PRE-EXPOSURE-PROPHYLAXIS-INFUSION

HCPCS M0224: Pemivibart IV Infusion for Pre-Exposure Prophylaxis

HCPCS-M0234-TOCILIZUMAB-INFUSION-HOSPITALIZED-COVID19

HCPCS Level II M0234: Tocilizumab-aazg IV Infusion, Second Dose

Showing 1–10 of 27

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Jul 29, 2026.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Modifier	Description	When to Use
`25`	Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure	When an E/M visit meets criteria in addition to the infusion service on the same date
`59`	Distinct procedural service	When another non-overlapping procedure is performed the same day and documentation supports distinct service
`76`	Repeat procedure or service by same physician	When the first-dose infusion is repeated by the same provider on the same day for clinical reasons
`77`	Repeat procedure by another physician	When a different physician repeats the infusion procedure on the same day
`90`	Reference (Outside) Laboratory	When laboratory testing associated with the infusion is performed by an outside reference lab
`91`	Repeat clinical diagnostic laboratory test	When an identical lab test is repeated within the same encounter for clinical reasons
`Q0`	Investigational clinical service provided in a clinical research study, not otherwise specified	If the infusion is provided under a clinical trial protocol that uses this modifier per payer rules
`Q5`	Service furnished under a clinic consortium agreement	When applicable per contractual arrangements with participating entities
`GA`	Waiver of liability statement on file (patient refuses payment)	When a signed Advance Beneficiary Notice or similar is on file for payors that require it
`G0`	Emergency use of a non‑approved device or service	If applicable for payors recognizing emergency use authorization circumstances

Taxonomy Code	Specialty	Notes
`207RC0000X`	Infectious Disease	Consultants who recommend and manage immunomodulatory therapy
`2084P0800X`	Critical Care Medicine	Intensivists managing mechanically ventilated or ECMO patients
`207K00000X`	Allergy & Immunology	Specialists involved in cytokine-modulating therapy decisions
`207L00000X`	Pulmonary Disease	Pulmonologists managing severe COVID-19 respiratory failure
`163W00000X`	Hospitalist	Hospital-based physicians who coordinate inpatient ordering and administration

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J12.82`	Pneumonia due to coronavirus disease 2019 (COVID-19)	Primary diagnosis indicating viral pneumonia requiring supplemental oxygen and qualifying for tocilizumab
`J96.01`	Acute respiratory failure with hypoxia	Indicates respiratory compromise often present in patients receiving `M0233`
`J80`	Acute respiratory distress syndrome	Severe pulmonary inflammation that may prompt use of immunomodulatory therapy
`R09.02`	Hypoxemia	Describes the need for supplemental oxygen documented for `M0233` eligibility
`B97.29`	Other coronavirus as the cause of diseases classified elsewhere	Alternate coding for COVID-19-related conditions when applicable

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	May be used for other IV infusions given before or after the tocilizumab infusion when billed separately
`96366`	Each additional hour (list separately in addition to code for primary infusion)	When the infusion duration extends beyond the initial hour and payer allows separate reporting
`36415`	Collection of venous blood by venipuncture	Performed before infusion for baseline labs (CBC, CMP, liver enzymes)
`99223`	Initial hospital care, typically 70 minutes or more	Hospitalist or intensivist initial admission evaluation for a critically ill patient who will receive `M0233`
`93000`	Electrocardiogram, routine ECG with at least 12 leads; tracing and interpretation	Performed when cardiac monitoring or baseline ECG is clinically indicated prior to immunomodulatory therapy

HCPCS M0075: Cellular Therapy Processing and Provision

HCPCS-M0076-PROLOTHERAPY-INJECTION-THERAPY

HCPCS M0076: Prolotherapy Injection Therapy

HCPCS-M0100-INTRAGASTRIC-HYPOTHERMIA-GASTRIC-FREEZING

HCPCS M0100: Intragastric Hypothermia Using Gastric Freezing

HCPCS-M0201-IN-HOME-VACCINE-ADMINISTRATION

HCPCS M0201: In-Home Administration of Pneumococcal/Influenza/Hep B/COVID-19 Vaccine

HCPCS-M0220-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS

HCPCS M0220: Tixagevimab and Cilgavimab Injection for Pre-Exposure Prophylaxis

HCPCS-M0221-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS-HOME-ADMINISTRATION

HCPCS M0221: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

HCPCS-M0222-BEBTELOVIMAB-INTRAVENOUS-INJECTION-MONITORING

HCPCS M0222: Intravenous Injection of Bebtelovimab, Includes Monitoring

HCPCS-M0223-BEBTELOVIMAB-INTRAVENOUS-INJECTION-HOME-MONITORING

HCPCS M0223: Bebtelovimab IV Injection with Home Monitoring

HCPCS-M0224-PEMIVIBART-PRE-EXPOSURE-PROPHYLAXIS-INFUSION

HCPCS M0224: Pemivibart IV Infusion for Pre-Exposure Prophylaxis

HCPCS-M0234-TOCILIZUMAB-INFUSION-HOSPITALIZED-COVID19

HCPCS Level II M0234: Tocilizumab-aazg IV Infusion, Second Dose

Showing 1–10 of 27

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Jul 29, 2026.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Jul 29, 2026.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

OpenPayer

HCPCS Level II M0233: Tocilizumab Intravenous Infusion, First Dose for Hospitalized Adults

Sign up for hcpcs M0233 policy alerts

Billing Code Overview

Catch payer policy changes before they impact reimbursement

Catch payer policy changes before they impact reimbursement

OpenPayer

HCPCS Level II M0233: Tocilizumab Intravenous Infusion, First Dose for Hospitalized Adults

Sign up for hcpcs M0233 policy alerts

Billing Code Overview

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

References

Clinical & Coding Specifications

Clinical Context

Coding Specifications

Related Diagnoses

Related CPT Codes

Related Codes

References